decisionhealth Newsletters, Coder Pink Sheets - 2008 Issue 9 (September)
No coverage for screening DNA stool test
Subscribe or sign in to view the full article.
Article Overview
This article discusses Medicare coverage status for a commercially available stool DNA screening test for colorectal cancer and explains why CMS deferred a national coverage decision pending FDA approval. It is relevant to primary care practices, coders, billing staff, and compliance teams who need to understand current federal screening coverage policy and where to look for official Medicare guidance on colorectal cancer screening services.
Why This Topic Matters
The article helps readers determine whether a stool DNA colorectal cancer screening service may be reimbursable under Medicare and points to the official CMS manuals and transmittal that govern related screening benefits. It is useful for practices evaluating preventive screening options and verifying payer policy before offering or billing for the test.
What You Will Learn
- The Medicare coverage context for stool DNA colorectal cancer screening
- How CMS and FDA roles affect coverage consideration for new screening tests
- Where to find official Medicare resources for colorectal cancer screening coverage policy
- How the article frames the relationship between stool DNA testing and other screening options at a broad policy level
Who Should Read This
- Primary care physicians
- Medical coders
- Billing staff
- Compliance professionals
- Practice administrators
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com